Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Lee's Pharm and RegeneRx Use New China Rules to Speed Eye Drug Development

publication date: Jun 1, 2016
Lee's Pharm of Hong Kong and US-based RegeneRx will take advantage of new China regulations to accelerate development of a treatment for dry eye syndrome. In April, the CFDA announced it would allow companies to use foreign-made drugs in Phase I and II clinical trials of domestically sponsored drugs. Accordingly, Lee's will use RegeneRx-supplied drugs for early stage testing, though Lee's will use its own China facilities to produce clinical trial supplies for Phase III. In 2012, Lee's in-licensed China rights to RGN-259 as part of a three-drug package. More details.....

Stock Symbols: (HK: 0950) (OTCQB: RGRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital